CLSA Applauds U.S. House Passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act
1379 reauthorizes key federal programs to bolster U.S. public health preparedness and response capabilities
Washington, D.C., San Francisco & San Diego, CA – June 4, 2019 – California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, applauds today’s U.S. House passage of S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019.
The legislation is key to strengthening our national preparedness and response for public health emergencies and accelerating medical countermeasure research and development. The reauthorization bill was previously approved by U.S. Senate on May 16, and now goes to President Trump for his signature. The following statement can be attributed to Mike Guerra, President & CEO, CLSA:
“California Life Sciences Association (CLSA) applauds today’s U.S. House passage of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPAI) of 2019, reauthorization legislation that will strengthen and improve our national preparedness and response for public health emergencies and accelerate medical countermeasure R&D. The programs authorized by PAHPAI have been essential to the nation’s preparedness and response for all populations to threats both naturally-occurring—like Ebola and pandemic influenza—and deliberate, such as a chemical, biological, radiological, or nuclear (CBRN) attack. The Ebola and Zika outbreaks, as-well-as ongoing threats from terrorist organizations like ISIS, have repeatedly exposed our nation’s continued vulnerability to bioterror and pandemic threats, demonstrating the need for robust biodefense preparedness.
“CLSA has worked diligently on behalf of our membership to get this legislation to the President’s desk. We applaud the leadership of House Energy and Commerce Health Subcommittee Chairwoman Anna G. Eshoo (D-Silicon Valley), Congresswoman Susan W. Brooks (R-Ind.), Senator Richard Burr (R-N.C.), and Senator Bob Casey (D-Pa.) for their bipartisan work on this important bill. On behalf of California’s life sciences sector, an industry with over 3,400 firms employing over 311,000 people, we urge President Trump to swiftly sign this bill into law and bolster our nation’s biodefense preparedness and response capabilities.”
Click here to view support letter and learn more about the bill.
- Learn Moreabout the California life sciences sector
- ViewCLSA’s Legislative Action Center
- WatchCLSA’s Faces of California Biomedical Innovation Web Series
- ViewUpcoming CLSA events
- Meetthe CLSA Board of Directors
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn andYouTube.
California Life Sciences Association (CLSA)
Will Zasadny | Director, Communications
firstname.lastname@example.org | 619-961-8848